Cited by 505Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Inoue, Akira, Kobayashi, Kunihiko, Usui, Kazuhiro, Maemondo, Makoto, Okinaga, Shoji, Mikami, Iwao, Ando, Masahiro, Yamazaki, Koichi, Saijo, Yasuo, Gemma, Akihiko, Miyazawa, Hitoshi, Tanaka, Tomoaki, Ikebuchi, Kenji, Nukiwa, Toshihiro, Morita, Satoshi, Hagiwara, Koichi·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2008.18.7658

Open this paper in CoChat — free account

Abstract

Purpose This multicenter phase II study was undertaken to investigate the efficacy and feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations without indication for chemotherapy as a result of poor performance status (PS). Patients and Methods Chemotherapy-naïve patients with poor PS (patients 20 to 74 years of age with Eastern Cooperative Oncology Group PS 3 to 4, 75 to 79 years of age with PS 2 to 4, and ≥ 80 years of age with PS 1 to 4) who had EGFR mutations examined by the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method were enrolled and received gefitinib (250 mg/d) alone. Results Between February 2006 and May 2007, 30 patients with NSCLC and poor PS, including 22 patients with PS 3 to 4, were enrolled. The overall response rate was 66% (90% CI, 51% to 80%), and the disease control rate was 90%. PS improvement rate was 79% (P < .00005); in particular, 68% of the 22 patients improved from ≥ PS 3 at baseline to ≤ PS 1. The median progression-free survival, median survival time, and 1-year survival rate were 6.5 months, 17.8 months, and 63%, respectively. No treatment-related deaths were observed. Conclusion This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib. Because there previously has been no standard treatment for these patients with short life expectancy other than best supportive care, examination of EGFR mutations as a biomarker is recommended in this patient population.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.7658

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W. T., Smith, T. J., Baker, S., Olak, J., Stover, D. E., Strawn, J. R., Turrisi, A. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,411

Show all 32 references

Research works printed but not linked: 1

Arteaga CL, ASCO virtual meeting 2004

Sorted by citations

Items 301–400 of 501

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
Normanno, N., Carotenuto, P., Roma, C., Rachiglio, A. M., Pasquale, R., Franco, R., Antinolfi, G., Piantedosi, Illiano, Botti, G., et al. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6626 · Cited by 7
Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study
Nagai, H., Shimada, T., Takahashi, Y., Nishikawa, M., Tozuka, H., Yamamoto, Y., Niwa, O., Takahara, Y., Fujita, A., Nagase, K., et al. (2022) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-022-00258-7 · Cited by 6
Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database
Okuma, Y., Shintani, Y., Sekine, I., Shukuya, T., Takayama, K., Inoue, A., Okamoto, I., Kiura, K., Yamamoto, N., Kawaguchi, T., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.01.005 · Cited by 6
Self-citation
Lung Cancer in Women
Graham, P. D., Thigpen, S. C., & Geraci, S. A. (2013) · Southern Medical Journal · doi:10.1097/smj.0000000000000004 · Cited by 6
EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC
Gorden, K. J., Mesbah, P., & Kolesar, J. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211408373 · Cited by 6
Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer
Kashiwabara, K., Semba, H., Fujii, S., & Tsumura, S. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.06.007 · Cited by 6
Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
Inoue, A. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.020 · Cited by 6
Self-citation
Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study
Aregui, A., Pluvy, J., Sanchez, M., Israel, T., Esnault, H., Guyard, A., Meyer, M., Khalil, A., Zalcman, G., Raynaud-Simon, A., et al. (2022) · Cancers · doi:10.3390/cancers14051344 · Cited by 6
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
Nadal, E., Oré-Arce, M., Remón, J., Bernabé, R., Covela, M., de Castro, J., Massutí-Sureda, B., Guillot-Morales, M., Majem, M., Maestu, I., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03286-3 · Cited by 7
Molecular epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: A single-center experience from India
Thomas, R., Balaram, G., Varayathu, H., Ghorpade, S. N., Kowsik, P. V., Dharman, B., Thomas, B. E., Ramaswamy, V., Nanjaiah, T. B., Patil, S. G., et al. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1986_21 · Cited by 6
To Crush or Not to Crush: Administering Dabrafenib and Trametinib Through a Nasogastric Tube in a Critically Ill Patient With Nonsmall Cell Lung Cancer – A Case Report and Review of Literature of Targeted Therapies Given Through Enteral Feeding Tubes
Jang, C., Lau, S. C. M., & Velcheti, V. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.12.013 · Cited by 6
Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?
Levy, B. P., Drilon, A. E. D. C., Makarian, L., Patel, A. A., & Grossbard, M. L. (2010) · PubMed · Cited by 6
Recent Development of Molecular-Targeted Drugs in Lung Cancer
Saijo, N., & Kenmotsu, H. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3845 · Cited by 6
Sensitivity and resistance to EGF-R inhibitors
Peipp, M., Dechant, M., & Valerius, T. (2009) · mAbs · doi:10.4161/mabs.1.6.10051 · Cited by 6
Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis
Okuda, T., Hayashi, H., Fujita, M., YOSHIOKA, H., Tasaki, T., Nakagawa, K., & Kato, A. (2013) · International Cancer Conference Journal · doi:10.1007/s13691-013-0148-0 · Cited by 6
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group
Califano, R., Griffiths, R., Lorigan, P. C., Ashcroft, L., Taylor, P. D., Burt, P. A., Lee, L. W., Chittalia, A., Harris, M., Finn, C. F., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.001 · Cited by 6
Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer
Mizota, A., Shitara, K., Kondo, C., Nomura, M., Yokota, T., Takahari, D., Ura, T., Inaba, Y., Yamaura, H., Sato, Y., et al. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0216-4 · Cited by 6
Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
Tanaka, H., Taima, K., Morimoto, T., Nakamura, K., Tanaka, Y., Itoga, M., Takanashi, S., & Okumura, K. (2016) · BMC Research Notes · doi:10.1186/s13104-016-1983-9 · Cited by 6
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Niu, H., Zhou, J., Maan, H., Markman, M. M., & Niu, J. (2017) · Case Reports in Oncology · doi:10.1159/000480452 · Cited by 6
Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
Dotsu, Y., Fukuda, M., Honda, N., Gyotoku, H., Kohno, Y., Suyama, T., Umeyama, Y., Taniguchi, H., Takemoto, S., Yamaguchi, H., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13756 · Cited by 6
A systematic review of the budget impact analyses for antitumor drugs of lung cancer
Han, L., Zhang, X., Fu, W., Sun, C., Zhao, X.-M., Zhou, L., & Liu, G. (2020) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-020-00253-5 · Cited by 6
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents
Saito, G., Ebata, T., Ishiwata, T., Iwasawa, S., Yoshino, I., Takiguchi, Y., & Tatsumi, K. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-020-05880-5 · Cited by 6
Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer: A prospective, multicenter, dose‐modification study
Tsubata, Y., Masuda, T., Hamai, K., Taniwaki, M., Tanino, A., Hotta, T., Hamaguchi, M., Hamaguchi, S., Yamasaki, M., Ishikawa, N., et al. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14243 · Cited by 6
First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
Losanno, T., & Gridelli, C. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01105-y · Cited by 6
Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice
Lam, Y. W. F. (2014) · Apple Academic Press eBooks · doi:10.1201/b17137-6 · Cited by 6
Problems involved in the clinical trials for non-small cell lung carcinoma
Saijo, N. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.001 · Cited by 6
Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer
Murakami, S., Saito, H., Kondo, T., Ito, H., Oshita, F., & Yamada, K. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3460-0 · Cited by 6
The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
Chang, S., Chang, C., & Shih, J. (2011) · Cancers · doi:10.3390/cancers3022667 · Cited by 6
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia
Suzumura, T., Yonesaka, K., Tsukuda, H., & Fukuoka, M. (2014) · BMJ Case Reports · doi:10.1136/bcr-2013-202705 · Cited by 6
Successful alectinib treatment for a mechanically ventilated patient with ALK-positive non-small cell lung cancer
Watanabe, Y., Koyama, N., Iwai, Y., Kawamura, R., Miwa, C., Nagai, Y., Hagiwara, K., & Koyama, S. (2016) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.24.47 · Cited by 6
Self-citation
Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report
Neto, F. L., de Sousa, L. G., Lewis, W. E., Glisson, B. S., Heymach, J. V., Tsao, A. S., & Ferrarotto, R. (2021) · Journal of Intensive Care Medicine · doi:10.1177/08850666211061312 · Cited by 5
3) Non-small Cell Lung Cancer
Kobayashi, K. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.2520 · Cited by 5
Self-citation
[Personalized targeted therapy for lung cancer].
Wu, K., House, L. K., Liu, W., & Cho, W. C. S. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.08.10 · Cited by 5
Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status
Karim, N. A., Musaad, S. M. A., Zarzour, A., Patil, S. B., & Jazieh, A. R. (2014) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s15172 · Cited by 5
Utility of Endoscopic Ultrasound with Bronchoscope-guided Fine-needle Aspiration for Detecting Driver Oncogenes in Non-small-cell Lung Cancer during Emergency Situations: Case Series
Nakashima, K., Demura, Y., Oi, M., Tabata, M., Tada, T., Shiozaki, K., Akai, M., & Ishizuka, T. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5594-20 · Cited by 5
Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report
Christofyllakis, K., Monteiro, A. R., Cetin, O., Kos, I. A., Greystoke, A., & Luciani, A. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.04.013 · Cited by 5
A population-based analysis of outcomes after radiotherapy in intensive care unit patients with lung cancer
Louie, A. V., Li, L., Jenkyn, K. B., Allen, B. N., Rodrigues, G., Warner, A., Palma, D. A., & Shariff, S. Z. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.05 · Cited by 5
Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings
Carver, J. R., & Desai, C. J. (2010) · Wiley eBooks · doi:10.1002/9780470660379.ch5 · Cited by 5
Clinical efficacy of osimertinib for a patient with ileus due to peritoneal carcinomatosis
Kawaguchi, Y., Hanaoka, J., Hayashi, H., Fukuda, Y., Iihara, H., Suzuki, A., & Sugiyama, T. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2645 · Cited by 4
Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study
Pathak, N., Garg, R. K., Khurana, S., Kumar, S., Kumar, A., Pushpam, D., Khan, M. A., Mohan, A., Pathy, S., Yadav, M., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04617-1 · Cited by 4
QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review
Khokhar, B., Chiang, B., Iglay, K., Reynolds, K. R., Rodriguez‐Ormaza, N., Spalding, W. M., & Freedland, E. S. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.02.005 · Cited by 4
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy
Popat, S., Januszewski, A. P., O'Brien, M. E. R., Ahmad, T., Lewanski, C. R., Dernedde, U., Jankowska, P., Mulatero, C., Shah, R. N. H., Hicks, J. R., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02901-6 · Cited by 4
Lung cancer screening with volume computed tomography is cost-effective in Greece
Pan, X., Togka, K., ten Berge, H., de Jong, L. A., Groen, H. J. M., Postma, M. J., Ζervas, Ε., Gkiozos, I., Foroulis, C., Tavernaraki, K., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316351 · Cited by 4
What Is the Relationship Between Patient Performance Status and Ability to Offer Chemotherapeutic Treatments?
Ramchandran, K. J., & Roenn, J. H. V. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-3796-7.00050-1 · Cited by 4
Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
Zukin, M. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70190-2 · Cited by 4
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer
Meriggi, F. A., & Zaniboni, A. (2010) · Current Gerontology and Geriatrics Research · doi:10.1155/2010/348174 · Cited by 4
Les avancées dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le réanimateur
Pinsolle, J., Terzi, N., Ferrer, L., Levra, M. G., Toffart, A., & Moro‐Sibilot, D. (2019) · Médecine Intensive Réanimation · doi:10.3166/rea-2019-0091 · Cited by 4
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
Lamberti, G., Andrini, E., & Ricciuti, B. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.104 · Cited by 4
Does progress achieved in the treatment of patients with metastatic non‐small‐cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland
Schmid, S., Šuipytė, J., Herrmann, C., Mousavi, S. M., Hitz, F., & Früh, M. (2020) · European Journal of Cancer Care · doi:10.1111/ecc.13206 · Cited by 4
Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective
Bosch‐Barrera, J., MARGALL, N. Q., & Brunet, J. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.007 · Cited by 4
A Case of Adenosquamous Lung Carcinoma with Dermatomyositis as a Paraneoplastic Syndrome
Tomoda, Y., Haruta, Y., Mei, T., Miyazaki, Y., & 餘家, 浩. (2013) · Haigan · doi:10.2482/haigan.53.870 · Cited by 4
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1
Gately, K. A., O’Flaherty, J. D., Cappuzzo, F., Pirker, R., Kerr, K. M., & O'Byrne, K. J. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200275 · Cited by 35
Management of Metastatic Nonsmall Cell Lung Cancer in Elderly
Sheth, H., Kumar, P., & Limaye, S. A. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1732784 · Cited by 3
Gefitinib: an “orphan” drug for non-small cell lung cancer
Ziogas, D. C., Liontos, M., Kyriazoglou, A. I., Tsironis, G., Bamias, A., & Dimopoulos, M. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1392852 · Cited by 3
Dramatic Response to Alectinib in a Critically Ill Elderly Patient with Lung Adenocarcinoma Due to Trousseau Syndrome and Disseminated Intravascular Coagulation
Hamada, N., Tada, Y., Hisamatsu, K., Yamamoto, Y., & Yamano, T. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7048-21 · Cited by 3
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
Fukui, T., Sasaki, J., Igawa, S., Kada, A., Saito, T. I., Kogure, Y., Okamoto, H., & Naoki, K. (2022) · BMC Cancer · doi:10.1186/s12885-022-10409-6 · Cited by 3
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
Ferreira, M., Swalduz, A., Greillier, L., du Rusquec, P., Curcio, H., Raimbourg, J., Toffart, A., Gounant, V., Couraud, S., Chabot, G. D., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107934 · Cited by 3
A Case of Advanced Gastric Cancer with Poor Performance Status Which Improved by Chemotherapy
Shitara, K., & Takahari, D. (2010) · Case Reports in Oncology · doi:10.1159/000319169 · Cited by 3
Current status and future perspectives of cooperative study groups for lung cancer in Japan
Kawano, Y., Okamoto, I., Fukuda, H., Ohe, Y., Nakamura, S., Nakagawa, K., Hotta, K., Kiura, K., Takiguchi, Y., Saka, H., et al. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.06.004 · Cited by 3
Self-citation
Prise en charge thérapeutique des cancers bronchiques non à petites cellules métastatiques mutés pour l'EGFR
Cadranel, J. L., Ruppert, A.-M., Lavolé, A., Gounant, V., Beau‐Faller, M., & Wislez, M. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70309-9 · Cited by 3
Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?
Brueckl, W. M., Wiest, G., & Ficker, J. H. (2010) · Pneumologie · doi:10.1055/s-0030-1255532 · Cited by 3
Administration of crizotinib through gastrostoma resolves esophageal occlusion caused by lymph node metastasis of squamous cell lung cancer with ROS1 fusion gene: a case report
Nakayama, M., Nagai, Y., Uchiyama, A., Saito, T., Iwanami, N., Hanawa, K., Okuyama, A., Sano, T., Sato, H., Tabata, K., et al. (2019) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.27.24 · Cited by 3
Self-citation
Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
Kim, T.-W., Lee, K., & Lee, S. H. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s382722 · Cited by 3
Mutation of EGFR in Non-small Cell Lung Cancer, a Regional Study in Upper Egypt
Eid, S. S. M., Hamed, A., Abdelgawad, M., Mohamed, A. E.-S., Mohamed, A. O., Mohamed, D. O., Sayed, M. M., Elgezawy, E., & Eldien, H. M. S. (2020) · Cancer Research Journal · doi:10.11648/j.crj.20200801.11 · Cited by 3
Association of Pretreatment Albumin-bilirubin Grade With Hepatotoxicity and Efficacy in EGFR-TKIs Therapy for NSCLC
Arihara, H., Nagamatsu, H., Hayakawa, Y., Mase, H., Araya, T., & Kita, T. (2025) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10417 · Cited by 2
Carcinomatous meningitis and EGFR mutation
Ishikawa, R., Yamazaki, S., Mio, T., Kawashima, A., Masumoto, A., Shiono, A., Daito, H., Yamaguchi, O., Maeno, Y., Okano, T., et al. (2015) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.23.14 · Cited by 2
Self-citation
Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status
Nakashima, K., Kodama, H., Murakami, H., Takahashi, T., Kawakado, K., Yanagawa, T., Kitani, K., Takamasa, H., Abe, M., Hamai, K., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.09.010 · Cited by 2
Prélèvement et recherche de la mutation EGFR : quoi prélever, quand et comment tester ?
Cadranel, J. L., & Leprieur, E. G. (2011) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(11)70004-9 · Cited by 2
Quelle séquence de traitement chez les patients EGFR mutés ?
Besse, B., & Zalcman, G. (2011) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(11)70007-4 · Cited by 2
EGFR Mutation Testing in Non-Small Cell Lung Cancer
Sriram, K. B., Francis, S. M. S., Tan, M. E., Bowman, R., Yang, I. A., & Fong, K. M. (2010) · Current Respiratory Medicine Reviews · doi:10.2174/157339810793563776 · Cited by 2
How old is "too old" for translational research?
Vergnenégre, A., Corre, R., Léna, H., & Caer, H. L. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.03.03 · Cited by 2
Peritoneal relapse from lung adenocarcinoma after a response to EGFR-TKI
Satoh, H., Kagohashi, K., & Kurishima, K. (2013) · Tuberkuloz ve Toraks · doi:10.5578/tt.6534 · Cited by 2
Gefitinib in Patients with Advanced Non-small-Cell Lung Cancer
Knetki‐Wróblewska, M., Kowalski, D. M., Zajda, K., Płużański, A., Badurak, P., Janowicz-Żebrowska, A., Jaśkiewicz, P., & Krzakowski, M. J. (2012) · Advances in respiratory medicine · doi:10.5603/arm.27563 · Cited by 2
Complete Resection Following Alectinib Administration for Stage IIIA-N2 ALK-translocated Non-small Cell Lung Cancer
Kubo, S., Beppu, K., Morifuji, Y., Kawaguchi, T., Himeji, D., & Marutsuka, K. (2017) · Haigan · doi:10.2482/haigan.57.752 · Cited by 2
Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life
Hiramoto, S., Taniyama, T., Kikuchi, A., Hori, T., Yoshioka, A., & Inoue, A. (2021) · Palliative & Supportive Care · doi:10.1017/s147895152100002x · Cited by 2
Self-citation
Incorporating Pharmacogenomics in Drug Development
Yin, O. Q. P., & Vandell, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00003-6 · Cited by 3
Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: a case series and review of the literature
Sasaki, A., Fujimoto, Y., Inada, T., Ishizuka, A., Ehara, J., Ogita, S., & Norisue, Y. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-04145-z · Cited by 2
A Case Report of an EML4-ALK-positive Elderly Non-small Cell Lung Cancer Patient with a Poor PS Successfully Treated with Crizotinib
Nagamata, M., Okuma, Y., Hosomi, Y., Hishima, T., & Okamura, T. (2013) · Haigan · doi:10.2482/haigan.53.782 · Cited by 2
Guide to Targeted Therapies: EGFR mutations in NSCLC
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3 · Cited by 3
EGFR mutations in lung cancer
Verdú, M., Trias, I., Roman, R. A., Rodón, N., Pubill, C., Calvo, M., García‐Peláez, B., Diaz, O., & Puig, X. (2016) · Revista Española de Patología · doi:10.1016/j.patol.2016.04.006 · Cited by 2
Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR : quels inhibiteurs ? Quelles séquences thérapeutiques ?
Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30100-2 · Cited by 2
Contribution of Ectodomain Mutations in Epidermal Growth Factor Receptor to Signaling in Glioblastoma Multiforme
Rojas, M. L. (2011) · Digital Commons-TMC (Texas Medical Center) · Cited by 2
Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al
Corre, R., Léna, H., Vergnenégre, A., & CHOUAID, C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1105 · Cited by 2
[A case of the cerebellar atrophy and pseudo-hyperchloremia as a clue to diagnose chronic bromvalerylurea intoxication].
Makita, Y., Katayama, T., Kuroda, K., Aizawa, H., & Kikuchi, K. (1999) · PubMed · Cited by 2
EBUS guided trans-esophgeal cryobiopsy-two case reports
Santhakumar, S., Deshmukh, K., Mehta, S. S., Muthusamy, R. K., Venugopal, J., Deepak, T. H., Karthi, N., Sharmila, P. S., Joseph, A., & Kurdula, T. (2025) · Lung India · doi:10.4103/lungindia.lungindia_531_23 · Cited by 1
Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status
Evans, T. L. (2015) · American Journal of Hematology / Oncology® · Cited by 1
Clinical analysis of G efitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations
Li, R., Lou, Y., Zhang, Y., Shi, C., Xiong, L., Gu, A., & Han, B. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12044 · Cited by 1
Crizotinib for the treatment of non-small-cell lung cancer withALKgene rearrangements
Alamgeer, M., Rogers, T.-M., Fox, S. B., & Solomon, B. (2012) · Clinical Investigation · doi:10.4155/cli.12.84 · Cited by 1
Ethnic variation in response to EGFR inhibitors
Loong, H. H.-F., Wei, J., & Mok, T. S. K. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.04.003 · Cited by 1
Plasma fibrinogen levels are associated with epidermal growth factor receptor gene mutation in Chinese patients with non-small cell lung cancer
Zhu, J., Cai, L., Yang, H., Wen, Y., Wang, J., Rong, T., & Zhang, L. (2013) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-013-1151-9 · Cited by 1
Development of Targeted Agents and Companion Diagnostics
Gérard, B., Bétard, M.-C., Smith, B., & Denyer, M. (2012) · Drug Information Journal · doi:10.1177/0092861512444032 · Cited by 1
Targeted Therapies for Non-small-Cell Lung Cancer
Metro, G., & Crinò, L. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_4 · Cited by 1
Management of elderly patients.
Vergnenégre, A., Corre, R., Léna, H., & Caer, H. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.04 · Cited by 1
A Case of Small-cell Lung Carcinoma with EGFR Gene Mutation
Narumi, S., Inoue, A., Shibahara, T., Igusa, R., Sakakibara, T., & Nukiwa, T. (2011) · Haigan · doi:10.2482/haigan.51.798 · Cited by 1
Self-citation
A Patient with Squamous Cell Carcinoma of the Lung and a Poor Performance Status Who Improved with S-1 Monotherapy
Okumura, J., Taki, S., Sanda, R., Ota, A., Takagi, Y., & Sugino, Y. (2013) · Haigan · doi:10.2482/haigan.53.264 · Cited by 1
Spécificités de la prise en charge du CBNPC chez les sujets âgés
Corre, R., & Caer, H. L. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2637-1 · Cited by 1
Adenocarcinoma of the lung
Flieder, D. B., Borczuk, A., & Noguchi, M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139018760.030 · Cited by 1
[Clinical Experience with First-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with Brain Metastasis].
Dong, H., Cui, S., Pan, F., Dong, L., Niu, Y., Zhao, Y., Gu, A., Jin, X., & Jiang, L. (2017) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2017.02.06 · Cited by 1
Clinical Benefit of Chemotherapy for Small-Cell Lung Cancer Patients with Extremely Poor Performance Status (PS)
Yamaguchi, O., Kagamu, H., Mouri, A., Shiono, A., Utsugi, H., Miyauchi, S., Nishihara, F., Maeno, Y., Murayama, Y., & Kobayashi, K. (2018) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.26.1 · Cited by 1
Self-citation
Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
Kitadai, R., Okuma, Y., & Kawai, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s186213 · Cited by 1

Authors: Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., Miyazawa, H., Tanaka, T., Ikebuchi, K., Nukiwa, T., Morita, S., & Hagiwara, K.
Affiliations: Tohoku University (JP)
ORCID: Inoue, Akira
Kobayashi, Kunihiko
Usui, Kazuhiro
Maemondo, Makoto
Saijo, Yasuo
Gemma, Akihiko
Miyazawa, Hitoshi
Tanaka, Tomoaki
Ikebuchi, Kenji
Nukiwa, Toshihiro
Morita, Satoshi
Hagiwara, Koichi
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-03-20
Volume: 27
Issue: 9
Pages: 1394-1400
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.18.7658
OpenAlex: W2111191667
Cited by: 505
References: 32
Citations by year: 2026: 2 · 2025: 6 · 2024: 10 · 2023: 18 · 2022: 22 · 2021: 33 · 2020: 25 · 2019: 22 · 2018: 29 · 2017: 35 · 2016: 34 · 2015: 31 · 2014: 30 · 2013: 43 · 2012: 41
FWCI: 45.89
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: gefitinib, advanced non-small cell lung cancer, EGFR mutation, first-line therapy, poor performance status, chemotherapy-naive patients, EGFR mutation testing, overall response rate, progression-free survival, best supportive care
MeSH terms: Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Middle Aged, Mutation, Prospective Studies, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks